Alan C. Rigby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alan C. Rigby has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Kumaran Shanmugasundaram
3 shared publicationsMarianne A. Grant
Division of Molecular and Vascular Medicine, Center for Vascular Biology Research, Department of Medicine, Beth Israel Deaconess Medical Center, 99 Brookline Avenue, Boston, MA 02215, USA
3 shared publicationsLiwen Ye
2 shared publications- Seth L. Alper
Division of Nephrology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, and Department of Medicine, Harvard Medical School, Boston, USA
2 shared publications A. Grey Craig
The Clayton Foundation Laboratories for Peptide Biology
1 shared publicationAleksey Lomakin
Department of Physics, Massachusetts Institute of Technology, Cambridge, MA 02139; and
1 shared publication
Latest Publications
- Open Access
- 1 March 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (10) , 8534-8544
Solution Structure of the Guanine Nucleotide-binding STAS Domain of SLC26-related SulP Protein Rv1739c from Mycobacterium tuberculosis
- 1 March 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (10) , 8534-8544
Open AccessSolution Structure of the Guanine Nucleotide-binding STAS Domain of SLC26-related SulP Protein Rv1739c from Mycobacterium tuberculosis
- 1 July 2009
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 1 (4) , 577-581
Targeting Historically Refractory Interfaces: A Partnership Model that Accelerates Drug Discovery within an Expanded Haystack
- 1 July 2009
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 1 (4) , 577-581
Targeting Historically Refractory Interfaces: A Partnership Model that Accelerates Drug Discovery within an Expanded Haystack
- 14 March 2009
- Published by Springer Nature in Biomolecular NMR Assignments
- Vol. 3 (1) , 99-102
NMR assignment and secondary structure of the STAS domain of Rv1739c, a putative sulfate transporter of Mycobacterium tuberculosis
We report 1HN, 15N, and 13C resonance assignments for the 15.6 kDa STAS domain of the putative sulfate transporter of Mycobacterium tuberculosis, Rv1739c, using heteronuclear, multidimensional NMR spectroscopy. Rv1739c is a SulP anion permease, related in structure to the SLC26 gene family of metazoan anion exchangers and anion channels.
- 14 March 2009
- Published by Springer Nature in Biomolecular NMR Assignments
- Vol. 3 (1) , 99-102
NMR assignment and secondary structure of the STAS domain of Rv1739c, a putative sulfate transporter of Mycobacterium tuberculosis
We report 1HN, 15N, and 13C resonance assignments for the 15.6 kDa STAS domain of the putative sulfate transporter of Mycobacterium tuberculosis, Rv1739c, using heteronuclear, multidimensional NMR spectroscopy. Rv1739c is a SulP anion permease, related in structure to the SLC26 gene family of metazoan anion exchangers and anion channels.
- 28 January 2009
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 418 (1) , 103-112
Netropsin improves survival from endotoxaemia by disrupting HMGA1 binding to the NOS2 promoter
The inducible form of nitric oxide synthase (NOS2) plays an important role in sepsis incurred as a result of infection with Gram-negative bacteria that elaborate endotoxin. The HMGA1 (high-mobility group A1) architectural transcription factor facilitates NOS2 induction by binding a specific AT-rich Oct (octamer) sequence in the core NOS2 promoter via AT-hook motifs. The small-molecule MGB (minor-groove binder) netropsin selectively targets AT-rich DNA sequences and can interfere with transcription factor binding. We therefore hypothesized that netropsin would improve survival from murine endotoxaemia by attenuating NOS2 induction through interference with HMGA1 DNA binding to the core NOS2 promoter. Netropsin improved survival from endotoxaemia in wild-type mice, yet not in NOS2-deficient mice, supporting an important role for NOS2 in the beneficial effects of MGB administration. Netropsin significantly attenuated NOS2 promoter activity in macrophage transient transfection studies and the AT-rich HMGA1 DNA-binding site was critical for this effect. EMSAs (electrophoretic mobility-shift assays) demonstrated that netropsin interferes with HMGA1 NOS2 promoter binding and NMR spectroscopy was undertaken to characterize this disruption. Chemical shift perturbation analysis identified that netropsin effectively competes both HMGA1 DNA-binding AT-hooks from the AT-rich NOS2 promoter sequence. Furthermore, NOESY data identified direct molecular interactions between netropsin and A/T base pairs within the NOS2 promoter HMGA1-binding site. Finally, we determined a structure of the netropsin/NOS2 promoter Oct site complex from molecular modelling and dynamics calculations. These findings represent important steps toward refined structure-based ligand design of novel compounds for therapeutic benefit that can selectively target key regulatory regions within genes that are important for the development of critical illness.
- 28 January 2009
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 418 (1) , 103-112
Netropsin improves survival from endotoxaemia by disrupting HMGA1 binding to the NOS2 promoter
The inducible form of nitric oxide synthase (NOS2) plays an important role in sepsis incurred as a result of infection with Gram-negative bacteria that elaborate endotoxin. The HMGA1 (high-mobility group A1) architectural transcription factor facilitates NOS2 induction by binding a specific AT-rich Oct (octamer) sequence in the core NOS2 promoter via AT-hook motifs. The small-molecule MGB (minor-groove binder) netropsin selectively targets AT-rich DNA sequences and can interfere with transcription factor binding. We therefore hypothesized that netropsin would improve survival from murine endotoxaemia by attenuating NOS2 induction through interference with HMGA1 DNA binding to the core NOS2 promoter. Netropsin improved survival from endotoxaemia in wild-type mice, yet not in NOS2-deficient mice, supporting an important role for NOS2 in the beneficial effects of MGB administration. Netropsin significantly attenuated NOS2 promoter activity in macrophage transient transfection studies and the AT-rich HMGA1 DNA-binding site was critical for this effect. EMSAs (electrophoretic mobility-shift assays) demonstrated that netropsin interferes with HMGA1 NOS2 promoter binding and NMR spectroscopy was undertaken to characterize this disruption. Chemical shift perturbation analysis identified that netropsin effectively competes both HMGA1 DNA-binding AT-hooks from the AT-rich NOS2 promoter sequence. Furthermore, NOESY data identified direct molecular interactions between netropsin and A/T base pairs within the NOS2 promoter HMGA1-binding site. Finally, we determined a structure of the netropsin/NOS2 promoter Oct site complex from molecular modelling and dynamics calculations. These findings represent important steps toward refined structure-based ligand design of novel compounds for therapeutic benefit that can selectively target key regulatory regions within genes that are important for the development of critical illness.
- Open Access
- 1 November 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (47) , 32860-32869
Probing the Interaction between the Coiled Coil Leucine Zipper of cGMP-dependent Protein Kinase Iα and the C Terminus of the Myosin Binding Subunit of the Myosin Light Chain Phosphatase
- 1 November 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (47) , 32860-32869
Open AccessProbing the Interaction between the Coiled Coil Leucine Zipper of cGMP-dependent Protein Kinase Iα and the C Terminus of the Myosin Binding Subunit of the Myosin Light Chain Phosphatase
- Open Access
- 1 February 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (7) , 3932-3941
Heparin-induced cis- and trans-Dimerization Modes of the Thrombospondin-1 N-terminal Domain
- 1 February 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (7) , 3932-3941
Open AccessHeparin-induced cis- and trans-Dimerization Modes of the Thrombospondin-1 N-terminal Domain
- Open Access
- 16 October 2007
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (42) , 16522-16527
Familial Alzheimer's disease mutations alter the stability of the amyloid β-protein monomer folding nucleus
Amyloid β-protein (Aβ) oligomers may be the proximate neurotoxins in Alzheimer's disease (AD). Recently, to elucidate the oligomerization pathway, we studied Aβ monomer folding and identified a decapeptide segment of Aβ, 21 Ala– 22 Glu– 23 Asp– 24 Val– 25 Gly– 26 Ser– 27 Asn– 28 Lys– 29 Gly– 30 Ala, within which turn formation appears to nucleate monomer folding. The turn is stabilized by hydrophobic interactions between Val-24 and Lys-28 and by long-range electrostatic interactions between Lys-28 and either Glu-22 or Asp-23. We hypothesized that turn destabilization might explain the effects of amino acid substitutions at Glu-22 and Asp-23 that cause familial forms of AD and cerebral amyloid angiopathy. To test this hypothesis, limited proteolysis, mass spectrometry, and solution-state NMR spectroscopy were used here to determine and compare the structure and stability of the Aβ(21–30) turn within wild-type Aβ and seven clinically relevant homologues. In addition, we determined the relative differences in folding free energies (ΔΔ G f ) among the mutant peptides. We observed that all of the disease-associated amino acid substitutions at Glu-22 or Asp-23 destabilized the turn and that the magnitude of the destabilization correlated with oligomerization propensity. The Ala21Gly (Flemish) substitution, outside the turn proper (Glu-22–Lys-28), displayed a stability similar to that of the wild-type peptide. The implications of these findings for understanding Aβ monomer folding and disease causation are discussed.
- 16 October 2007
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (42) , 16522-16527
Open AccessFamilial Alzheimer's disease mutations alter the stability of the amyloid β-protein monomer folding nucleus
Amyloid β-protein (Aβ) oligomers may be the proximate neurotoxins in Alzheimer's disease (AD). Recently, to elucidate the oligomerization pathway, we studied Aβ monomer folding and identified a decapeptide segment of Aβ, 21 Ala– 22 Glu– 23 Asp– 24 Val– 25 Gly– 26 Ser– 27 Asn– 28 Lys– 29 Gly– 30 Ala, within which turn formation appears to nucleate monomer folding. The turn is stabilized by hydrophobic interactions between Val-24 and Lys-28 and by long-range electrostatic interactions between Lys-28 and either Glu-22 or Asp-23. We hypothesized that turn destabilization might explain the effects of amino acid substitutions at Glu-22 and Asp-23 that cause familial forms of AD and cerebral amyloid angiopathy. To test this hypothesis, limited proteolysis, mass spectrometry, and solution-state NMR spectroscopy were used here to determine and compare the structure and stability of the Aβ(21–30) turn within wild-type Aβ and seven clinically relevant homologues. In addition, we determined the relative differences in folding free energies (ΔΔ G f ) among the mutant peptides. We observed that all of the disease-associated amino acid substitutions at Glu-22 or Asp-23 destabilized the turn and that the magnitude of the destabilization correlated with oligomerization propensity. The Ala21Gly (Flemish) substitution, outside the turn proper (Glu-22–Lys-28), displayed a stability similar to that of the wild-type peptide. The implications of these findings for understanding Aβ monomer folding and disease causation are discussed.
- 1 April 2007
- Published by Informa Healthcare in Expert Opinion on Drug Discovery
- Vol. 2 (4) , 453-468
Conotoxin therapeutics: a pipeline for success?
The pharmacopoeia of conotoxins from the marine snail Conus has evolved with time, providing a myriad of molecular scaffolds on which critical, molecular pharmacophoric descriptors, responsible for mediating conotoxin receptor-target specificity and selectivity have been grafted. Several reports have defined how these critical determinants contribute to refined, subtype-selective receptor recognition. However, the clinical utility of conotoxins is debatable with a single conotoxin, ω-MVIIA (ziconotide), approved by the US FDA. The authors review the present status of conotoxin-based drug discovery efforts, highlighting ongoing preclinical and clinical studies, while discussing strategies that may be necessary to overcome the barriers inherent to peptide therapeutics. Through the beauty of nature and the art of design it should be possible to expand the Conus pipeline.
- 1 April 2007
- Published by Informa Healthcare in Expert Opinion on Drug Discovery
- Vol. 2 (4) , 453-468
Conotoxin therapeutics: a pipeline for success?
The pharmacopoeia of conotoxins from the marine snail Conus has evolved with time, providing a myriad of molecular scaffolds on which critical, molecular pharmacophoric descriptors, responsible for mediating conotoxin receptor-target specificity and selectivity have been grafted. Several reports have defined how these critical determinants contribute to refined, subtype-selective receptor recognition. However, the clinical utility of conotoxins is debatable with a single conotoxin, ω-MVIIA (ziconotide), approved by the US FDA. The authors review the present status of conotoxin-based drug discovery efforts, highlighting ongoing preclinical and clinical studies, while discussing strategies that may be necessary to overcome the barriers inherent to peptide therapeutics. Through the beauty of nature and the art of design it should be possible to expand the Conus pipeline.
- Open Access
- 7 December 2004
- Published by Wiley in European Journal of Biochemistry
- Vol. 271 (23-24) , 4939-4949
Total chemical synthesis and NMR characterization of the glycopeptide tx5a, a heavily post‐translationally modified conotoxin, reveals that the glycan structure is α‐d‐Gal‐(1→3)‐α‐d‐GalNAc
The 13‐amino acid glycopeptide tx5a (Gla‐Cys‐Cys‐Gla‐Asp‐Gly‐Trp*‐Cys‐Cys‐Thr*‐Ala‐Ala‐Hyp‐OH, where Trp* = 6‐bromotryptophan and Thr* = Gal‐GalNAc‐threonine), isolated from Conus textile, causes hyperactivity and spasticity when injected intracerebral ventricularly into mice. It contains nine post‐translationally modified residues: four cysteine residues, two γ‐carboxyglutamic acid residues, and one residue each of 6‐bromotryptophan, 4‐trans‐hydroxyproline and glycosylated threonine. The chemical nature of each of these has been determined with the exception of the glycan linkage pattern on threonine and the stereochemistry of the 6‐bromotryptophan residue. Previous investigations have demonstrated that tx5a contains a disaccharide composed of N‐acetylgalactosamine (GalNAc) and galactose (Gal), but the interresidue linkage was not characterized. We hypothesized that tx5a contained the T‐antigen, β‐d‐Gal‐(1→3)‐α‐d‐GalNAc, one of the most common O‐linked glycan structures, identified previously in another Conus glycopeptide, contalukin‐G. We therefore utilized the peracetylated form of this glycan attached to Fmoc‐threonine in an attempted synthesis. While the result‐ing synthetic peptide (Gla‐Cys‐Cys‐Gla‐Asp‐Gly‐Trp*‐Cys‐Cys‐Thr*‐Ala‐Ala‐Hyp‐OH, where Trp* =6‐bromotryptophan and Thr* = β‐d‐Gal‐(1→3)‐α‐d‐GalNAc‐threonine) and the native peptide had almost identical mass spectra, a comparison of their RP‐HPLC chromatograms suggested that the two forms were not identical. Two‐dimensional 1H homonuclear and 13C‐1H heteronuclear NMR spectroscopy of native tx5a isolated from Conus textile was then used to determine that the glycan present on tx5a indeed is not the aforementioned T‐antigen, but rather α‐d‐Gal‐(1→3)‐α‐d‐GalNAc.
- 7 December 2004
- Published by Wiley in European Journal of Biochemistry
- Vol. 271 (23-24) , 4939-4949
Open AccessTotal chemical synthesis and NMR characterization of the glycopeptide tx5a, a heavily post‐translationally modified conotoxin, reveals that the glycan structure is α‐d‐Gal‐(1→3)‐α‐d‐GalNAc
The 13‐amino acid glycopeptide tx5a (Gla‐Cys‐Cys‐Gla‐Asp‐Gly‐Trp*‐Cys‐Cys‐Thr*‐Ala‐Ala‐Hyp‐OH, where Trp* = 6‐bromotryptophan and Thr* = Gal‐GalNAc‐threonine), isolated from Conus textile, causes hyperactivity and spasticity when injected intracerebral ventricularly into mice. It contains nine post‐translationally modified residues: four cysteine residues, two γ‐carboxyglutamic acid residues, and one residue each of 6‐bromotryptophan, 4‐trans‐hydroxyproline and glycosylated threonine. The chemical nature of each of these has been determined with the exception of the glycan linkage pattern on threonine and the stereochemistry of the 6‐bromotryptophan residue. Previous investigations have demonstrated that tx5a contains a disaccharide composed of N‐acetylgalactosamine (GalNAc) and galactose (Gal), but the interresidue linkage was not characterized. We hypothesized that tx5a contained the T‐antigen, β‐d‐Gal‐(1→3)‐α‐d‐GalNAc, one of the most common O‐linked glycan structures, identified previously in another Conus glycopeptide, contalukin‐G. We therefore utilized the peracetylated form of this glycan attached to Fmoc‐threonine in an attempted synthesis. While the result‐ing synthetic peptide (Gla‐Cys‐Cys‐Gla‐Asp‐Gly‐Trp*‐Cys‐Cys‐Thr*‐Ala‐Ala‐Hyp‐OH, where Trp* =6‐bromotryptophan and Thr* = β‐d‐Gal‐(1→3)‐α‐d‐GalNAc‐threonine) and the native peptide had almost identical mass spectra, a comparison of their RP‐HPLC chromatograms suggested that the two forms were not identical. Two‐dimensional 1H homonuclear and 13C‐1H heteronuclear NMR spectroscopy of native tx5a isolated from Conus textile was then used to determine that the glycan present on tx5a indeed is not the aforementioned T‐antigen, but rather α‐d‐Gal‐(1→3)‐α‐d‐GalNAc.